Appraising the Tail of the Survival Curve in the Era of PD-1/PD-L1 Checkpoint Blockade
It has been 13 years since the first patients enrolled into the first-in-human trial evaluating MDX-11061 blocking the interaction between programmed-death 1 (PD-1), expressed in T cells on activation during priming or expansion, and its ligands programmed-death ligands 1 and 2 (PD-L1 and PD-L2), a…